SHR-1210 + SHR-1020 + Physician's choice chemotherapy
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent or Metastatic Cervical Cancer
Conditions
Recurrent or Metastatic Cervical Cancer
Trial Timeline
Apr 5, 2021 → Jul 7, 2025
NCT ID
NCT04680988About SHR-1210 + SHR-1020 + Physician's choice chemotherapy
SHR-1210 + SHR-1020 + Physician's choice chemotherapy is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Recurrent or Metastatic Cervical Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04680988. Target conditions include Recurrent or Metastatic Cervical Cancer.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent or Metastatic Cervical Cancer were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04680988 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent or Metastatic Cervical Cancer